Serum levels of pigment epithelium-derived factor (PEDF) are independently associated with procollagen III N-terminal peptide levels in patients with nonalcoholic fatty liver disease

Clinical Biochemistry

Volumn 45, Issue 18, 2012, Pages 1554-1557

  Hyogo, Hideyuki ^a   Yamagishi, Sho ichi ^b   Maeda, Sayaka ^b   Kimura, Yuki ^a   Ishitobi, Tomokazu ^a   Chayama, Kazuaki ^a  

^a HIROSHIMA UNIVERSITY   (Japan)

^b KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Fibrosis; Inflammation; NAFLD; PEDF

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; PIGMENT EPITHELIUM DERIVED FACTOR; PROCOLLAGEN; URIC ACID;

ADULT; ARTICLE; BIOPSY; BODY MASS; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; FATTY LIVER; FEMALE; FIBROSIS; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPERLIPIDEMIA; INTRAABDOMINAL FAT; LEUKOCYTE; LIVER; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; PRIORITY JOURNAL; SPLEEN; SUBCUTANEOUS FAT; THROMBOCYTE; WAIST CIRCUMFERENCE;

EYE PROTEINS; FATTY LIVER; FEMALE; HUMANS; MALE; MIDDLE AGED; NERVE GROWTH FACTORS; PEPTIDE FRAGMENTS; PROCOLLAGEN; REGRESSION ANALYSIS; SERPINS;

EID: 84870686406     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2012.07.106     Document Type: Article

References (39)

1. Teli M.R., James O.F., Burt A.D., Bennett M.K., Day C.P. The natural history of nonalcoholic fatty liver: a follow-up study. Hepatology 1995, 22:1714-1719.
2. Dam-Larsen S., Franzmann M., Andersen I.B., et al. Long term prognosis of fatty liver: risk of chronic liver disease and death. Gut 2004, 53:750-755.
3. Matteoni C.A., Younossi Z.M., Gramlich T., et al. Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity. Gastroenterology 1999, 116:1413-1419.
4. Chitturi S., Abeygunasekera S., Farrell G.C., et al. NASH and insulin resistance: insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 2002, 35:373-379.
5. Marchesini G., Brizi M., Bianchi G., et al. Nonalcoholic fatty liver disease: a feature of the metabolic syndrome. Diabetes 2001, 50:1844-1850.
6. Bhatia L.S., Curzen N.P., Calder P.C., Byrne C.D. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor?. Eur Heart J 2012, 33:1190-1200.
7. Petta S., Muratore C., Craxì A. Non-alcoholic fatty liver disease pathogenesis: the present and the future. Dig Liver Dis 2009, 41:615-625.
8. Hyogo H., Yamagishi S. Advanced glycation end products (AGEs) and their involvement in liver disease. Curr Pharm Des 2008, 14:969-972.
9. Day C.P., James O.F. Steatohepatitis: a tale of two "hits"?. Gastroenterology 1998, 114:842-845.
10. Tombran-Tink J., Chader C.G., Johnson L.V. PEDF: pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991, 53:411-414.
11. Dawson D.W., Volpert O.V., Gillis P., et al. Pigment epithelium-derived factor: a potent inhibitor of angiogenesis. Science 1999, 285:245-248.
12. Duh E.J., Yang H.S., Suzuma I., et al. Pigment epithelium-derived factor suppresses ischemia-induced retinal neovascularization and VEGF-induced migration and growth. Invest Ophthalmol Vis Sci 2002, 43:821-829.
13. Inagaki Y., Yamagishi S., Okamoto T., Takeuchi M., Amano S. Pigment epithelium-derived factor prevents advanced glycation end products-induced monocyte chemoattractant protein-1 production in microvascular endothelial cells by suppressing intracellular reactive oxygen species generation. Diabetologia 2003, 46:284-287.
14. Yamagishi S., Nakamura K., Matsui T., et al. Pigment epithelium-derived factor inhibits advanced glycation end product-induced retinal vascular hyperpermeability by blocking reactive oxygen species-mediated vascular endothelial growth factor expression. J Biol Chem 2006, 281:20213-20220.
15. Yamagishi S.I., Matsui T. Anti-atherothrombogenic properties of PEDF. Curr Mol Med 2010, 10:284-291.
16. Hoshina D., Abe R., Yamagishi S.I., Shimizu H. The role of PEDF in tumor growth and metastasis. Curr Mol Med 2010, 10:292-295.
17. Yamagishi S., Matsui T., Nakamura K. Atheroprotective properties of pigment epithelium-derived factor (PEDF) in cardiometabolic disorders. Curr Pharm Des 2009, 15:1027-1033.
18. Tombran-Tink J. The neuroprotective and angiogenesis inhibitory serpin, PEDF: new insights into phylogeny, function, and signaling. Front Biosci 2005, 10:2131-2149.
19. Yoshida T., Yamagishi S., Nakamura K., et al. Pigment epithelium-derived factor (PEDF) ameliorates advanced glycation end product (AGE)-induced hepatic insulin resistance in vitro by suppressing Rac-1 activation. Horm Metab Res 2008, 40:620-625.
20. Yamagishi S.I., Matsui T., Kawaguchi T., Sata M. Pathophysiological role of pigment epithelium-derived factor (PEDF) in hepatic disorders. Curr Med Chem 2010, 17:1995-2000.
21. Chung C., Doll J.A., Gattu A.K., et al. Anti-angiogenic pigment epithelium-derived factor regulates hepatocyte triglyceride content through adipose triglyceride lipase (ATGL). J Hepatol 2008, 48:471-478.
22. Shewan L.G., Coats A.J. Ethics in the authorship and publishing of scientific articles. Int J Cardiol 2010, 144:1-2.
23. Hyogo H., Tazuma S., Arihiro K., et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism 2008, 57:1711-1718.
24. Kimura Y., Hyogo H., Yamagishi S., et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol 2010, 45:750-757.
25. Yamagishi S., Adachi H., Abe A., et al. Elevated serum levels of pigment epithelium-derived factor in the metabolic syndrome. J Clin Endocrinol Metab 2006, 91:2447-2450.
26. Fukami K., Yamagishi S.I., Okuda S. Development of enzyme-linked immunosorbent assay system for PEDF and its clinical utility. Curr Mol Med 2010, 10:317-320.
27. Hyogo H., Yamagishi S., Iwamoto K., et al. Elevated levels of serum advanced glycation end products in patients with non-alcoholic steatohepatitis. J Gastroenterol Hepatol 2007, 22:1112-1119.
28. Ricci C., Longo R., Gioulis E., et al. Noninvasive in vivo quantitative assessment of fat content in human liver. J Hepatol 1997, 27:108-113.
29. Kleiner D.E., Brunt E.M., Van Natta M., et al. Nonalcoholic Steatohepatitis Clinical Research Network. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005, 41:1313-1321.
30. Yilmaz Y., Eren F., Ayyildiz T., et al. Serum pigment epithelium-derived factor levels are increased in patients with biopsy-proven nonalcoholic fatty liver disease and independently associated with liver steatosis. Clin Chim Acta 2011, 412:2296-2299.
31. Wang J.J., Zhang S.X., Mott R., et al. Salutary effect of pigment epithelium-derived factor in diabetic nephropathy: evidence for antifibrogenic activities. Diabetes 2006, 55:1678-1685.
32. Maeda S., Matsui T., Takeuchi M., et al. Pigment epithelium-derived factor (PEDF) inhibits proximal tubular cell injury in early diabetic nephropathy by suppressing advanced glycation end products (AGEs)-receptor (RAGE) axis. Pharmacol Res 2011, 63:241-248.
33. Ueda S., Yamagishi S., Matsui T., Jinnouchi Y., Imaizumi T. Administration of pigment epithelium-derived factor inhibits left ventricular remodeling and improves cardiac function in rats with acute myocardial infarction. Am J Pathol 2011, 178:591-598.
34. Ho T.C., Chen S.L., Shih S.C., et al. Pigment epithelium-derived factor is an intrinsic antifibrosis factor targeting hepatic stellate cells. Am J Pathol 2010, 177:1798-1811.
35. Schmitz J.C., Protiva P., Gattu A.K., et al. Pigment epithelium-derived factor regulates early pancreatic fibrotic responses and suppresses the profibrotic cytokine thrombospondin-1. Am J Pathol 2011, 179:2990-2999.
36. Chen C., Tso A.W., Law L.S., et al. Plasma level of pigment epithelium-derived factor is independently associated with the development of the metabolic syndrome in Chinese men: a 10-year prospective study. J Clin Endocrinol Metab 2010, 95:5074-5081.
37. Umei H., Yamagishi S.I., Imaizumi T. Positive association of serum levels of pigment epithelium-derived factor with high-sensitivity C-reactive protein in apparently healthy unmedicated subjects. J Int Med Res 2010, 38:443-448.
38. Palmieri D., Watson J.M., Rinehart C.A. Age-related expression of PEDF/EPC-1 in human endometrial stromal fibroblasts: implications for interactive senescence. Exp Cell Res 1999, 247:142-147.
39. Francis M.K., Appel S., Meyer C., et al. Loss of EPC-1/PEDF expression during skin aging in vivo. J Invest Dermatol 2004, 122:1096-1105.